Physician profile
Daniel J Johnson
NPI 1740206549
$1,150.21
in general payments reported to CMS, 2019-2025
28 companies · $531 in 2025
The $531 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $20.44 · 2023: $66.40 · 2024: $533 · 2025: $531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,129.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $295.61 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $160.22 | 2023-2024 | Ultomiris |
| Neurocrine Biosciences, INC. | $143.76 | 2024-2025 | Ingrezza |
| Globus Medical, INC. | $48.76 | 2025 | Senza |
| Aimmune Therapeutics, INC. | $48.12 | 2024-2025 | Zenpep, Vowst |
| Eisai INC. | $39.67 | 2025 | |
| Pfizer INC. | $35.49 | 2024 | |
| Tanabe Pharma America, INC. | $33.89 | 2025 | Radicava |
| Phathom Pharmaceuticals, INC. | $29.03 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $25.21 | 2024 | Hyqvia |
| Bayer Healthcare Pharmaceuticals INC. | $24.00 | 2025 | |
| Recordati_rare_diseases_inc. | $22.16 | 2025 | Isturisa |
| Amgen INC. | $21.83 | 2025 | Tepezza |
| Gilead Sciences, INC. | $21.73 | 2025 | |
| Intercept Pharmaceuticals, INC. | $21.26 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $17.52 | 2025 | Korlym |
| Almatica Pharma LLC | $16.73 | 2024 | Teriparatide |
| Tandem Diabetes Care, INC. | $16.68 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Alnylam Pharmaceuticals INC. | $16.61 | 2024 | Onpattro |
| Lilly USA, LLC | $14.82 | 2025 | Mounjaro, Zepbound |
| Abbott Laboratories | $14.81 | 2024 | Merlin@Home |
| Csl Behring | $14.71 | 2025 | Hizentra |
| Neurelis, INC. | $14.17 | 2025 | Valtoco |
| Astrazeneca Pharmaceuticals Lp | $13.91 | 2025 | Wainua |
| Tg Therapeutics, INC. | $13.22 | 2024 | |
| Lundbeck LLC | $13.21 | 2024 | Vyepti |
| Novo Nordisk INC | $13.08 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.